50 Leading Companies of the Year 2022
The Silicon Review
“ViewMind has shown in clinical studies that it can detect cognitive alterations in patients with Familial Alzheimer’s Disease (FAD) up to 20 years before symptoms.”
Biomarkers are the heart of disease diagnostics. The past decade has seen tremendous efforts in biomarker discovery and validation for neurodegenerative diseases. With the rise of digital health data collection, researchers and providers alike are embracing the potential of digital biomarkers. Digital biomarkers may provide a new, more robust method for diagnosing neurodegenerative diseases and monitoring the impact of treatment on cognition. They enable the collection and analysis of physiological and behavioral data, which may diagnose diseases such as Alzheimer’s, multiple sclerosis and other conditions.
ViewMind is a digital health and artificial intelligence company that provides clinically validated solutions for precision diagnostics of neurocognitive disorders. The company develops non-invasive evaluations for the early detection and management of Alzheimer’s and other dementias using revolutionary eye-tracking technology. Using cutting-edge technology in an immersive diagnosis allows for precise, neurocognitive health assessments, the likes of which have never been seen before. ViewMind’s pioneering work is not only revolutionary from a technological point of view, but the solutions the company has developed have been clinically validated, and their devices have been approved in several regions, including Europe.
Mark Edwards, CEO of ViewMind, spoke to The Silicon Review about how his company-built solution provides a suite of a novel digital biomarker for neurodegenerative disorders.
Q. Can you explain about your services in brief?
ViewMind is a Digital Health and Artificial Intelligence company that provides clinically validated solutions for the diagnosis of neurodegerative disorders and to measure the impact of treatment on cognition. ViewMind has developed a one-of-a-kind reliable, non-invasive, and accessible digital biomarker technology that delivers clinical results as accurate as today’s definitive tests. With the assistance of ViewMind, physicians will be able to diagnose neurodegeneratie disorders promptly. The information gathered from the ViewMind assessment will enable individuals to make informed decisions to potentially change the course of their future brain health. Knowing the answers to questions about an individual’s neurocognitive health will allow patients to make life-changing choices to take care of their brain and overall health proactively.
Q. Generally, diseases are detected and diagnosed by professional and trained technicians. How does your solution align with the existing medical practice?
There are two aspects of brain health; cognition and the brain’s physical health. Cognition is typically measured using pen and paper tests devised in the mid-20th century or computer and iPad based versions of similar tests. They mostly require a skilled assessor, and the results can vary between tests. ViewMind replaces these tests with a solution that has a vastly higher sensitivity for assessing cognition, and no specialized medical training is required to perform a diagnosis.
The diagnoses that measure the brain’s physical health are invasive and expensive tests like a lumbar puncture or PET scan. These assessments and neurocognitive testing are only performed when a person presents symptoms of neurocognitive impairment, which could be many years and even decades after the problem began and in many instances too late to reverse or halt the decline.
ViewMind correlates with these tests but with the advantage of being non-invasive, affordable, and accessible. The ViewMind assessment of cognitive abilities and the brain’s physical health are combined into an overall correlated evaluation of brain health.
Q. Tell us about the different applications for your technology and how it is different from the existing diagnostic practices.
ViewMind uses eye-tracking AI technology to aid in the diagnosis of neurocognitive diseases. Capturing around 100,000 data points, it is non-invasive, affordable, and accurate. It gives a full report on a patient’s cognitive health for a doctor to diagnose brain health. ViewMind’s technology provides new possibilities for a more accurate and earlier diagnosis of Alzheimer’s and other neurocognitive disorders. It delivers sensitivity and specificity four years before symptoms in longitudinal studies in the high 90 percent range. ViewMind has also shown in clinical studies that it can detect cognitive alterations in patients with Familial Alzheimer’s Disease (FAD) up to 20 years before symptoms. The pathology of FAD is similar to general Alzheimer’s in that Amyloid Beta deposits start to accumulate in specific regions of the brain.
Q. How do your offerings manage to get an accurate diagnosis to prompt treatment?
Alterations in cognition and brain health result in minor reproducible alterations in eye movements. ViewMind solution works by activating specific areas of the brain. The eye movement responses are captured. By analyzing the patient’s data with ViewMind’s AI, the patterns can be correlated with specific pathologies.
Without a specific diagnosis, a patient will not receive the proper treatment they require. ViewMind’s diagnostic report is accessible for doctors to access and understand. The information allows medical professionals to get an accurate view of the patient’s cognitive health.
Q. Do you have any new services ready to be launched?
ViewMind’s solution for brain health diagnosis is available in Europe and LATAM and is expected to be available in the US during 2022, subject to FDA approval.
Q. What does the future hold for your company and its customers? Are exciting things on the way?
ViewMind’s innovative solution has pioneered and paved the way for diagnosing neurocognitive disorders. With the power of AI, ViewMind can quickly, efficiently, and cost-effectively aid in diagnosing neurocognitive disorders. With such technology, there is huge potential for ViewMind to help millions of people around the world. Brain health screening will be part of general health screening and is affordable and accessible to all patients. ViewMind’s solution works independently of a person’s age, education and culture, making it the only technology that can precisely measure neurocognitive function without exterior influences.
The Visionary Leader at the Helm of ViewMind
Mark Edwards serves as the Chief Executive Officer of ViewMind. He is an experienced entrepreneur, CEO, seven times founder, board member, and builder of market leaders in private and public companies in the software, AI, hardware, and services industries.